1,583
Views
4
CrossRef citations to date
0
Altmetric
Commentary

Laboratory-based surveillance in Latin America: attributes and limitations in evaluation of pneumococcal vaccine impact

Pages 4667-4672 | Received 14 Jun 2021, Accepted 20 Aug 2021, Published online: 07 Oct 2021

Figures & data

Figure 1. Plain language summary.

Figure 1. Plain language summary.

Figure 2. Country-specific SIREVA-reported isolates of pneumococcal meningitis and sepsis/bacteremia versus estimated expected number of cases adjusted for vaccine impact in children aged <5 years, and percent difference between SIREVA-reported isolates and estimated cases, from year of higher-valent PCV introduction to latest year for which data are available.

PCV, pneumococcal conjugate vaccineYears represent the post-vaccination years for higher-valent PCVs in all countries. Proportion of reported isolates over estimated cases represents the number of isolates reported by SIREVA out of the estimated number of cases based on regional incidence rates (% Reported = Reported Cases/Estimated Cases).
Figure 2. Country-specific SIREVA-reported isolates of pneumococcal meningitis and sepsis/bacteremia versus estimated expected number of cases adjusted for vaccine impact in children aged <5 years, and percent difference between SIREVA-reported isolates and estimated cases, from year of higher-valent PCV introduction to latest year for which data are available.